{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:40:31Z","timestamp":1791380431849,"version":"4.3.3"},"reference-count":25,"publisher":"MedWorks Media","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>The atypical antipsychotic, quetiapine has been on market for years now with long track record. In child and adolescent psychiatry, it is FDA-approved for childhood-onset schizophrenia and juvenile bipolar mood disorder. Its attractive pharmacological portfolio speaks to the idea of a versatile pluripotent broad-spectrum psychotropic agent expanding its therapeutic potential on clinical grounds. In this focussed review, authors brief these clinical indications whilst examining the extant evidence.<\/jats:p>","DOI":"10.64719\/pb.4532","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:23:34Z","timestamp":1761045814000},"page":"31-36","source":"Crossref","is-referenced-by-count":0,"title":["Quetiapine and Paediatric Psychiatrica: Evidence or Diffidence?"],"prefix":"10.64719","volume":"55","author":[{"given":"Ahmed","family":"Naguy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saxby","family":"Pridmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hend FM FR","family":"Alenezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibi","family":"Alamiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Berger GE, Proffitt TM, McConchie M et al. Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg\/day vs. 400 mg\/day of quetiapine fumarate in 141 patients aged 15 to 25 years. J Clin Psychiatry. 2008;69(11):1702\u20131714.","DOI":"10.4088\/JCP.v69n1105"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Pagsberg AK, Jeppesen P, Klauber DG et al. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. Lancet Psychiatry. 2017;4(8):605\u2013618.","DOI":"10.1016\/S2215-0366(17)30166-9"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Pathak S, Findling RL, Earley WR et al. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74(1):e100\u2013e109.","DOI":"10.4088\/JCP.11m07424"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Delbello MB, Kowatch RA, Adler CA et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2006;45(3):305\u2013313.","DOI":"10.1097\/01.chi.0000194567.63289.97"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Srinivas S, Parvataneni T, Makani R et al. Efficacy and Safety of Quetiapine for Pediatric Bipolar Depression: A Systematic Review of Randomized Clinical Trials. Cureus. 2020;12(6):e8407.","DOI":"10.7759\/cureus.8407"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Connor DF, McLaughlin TJ, Jeffers-Terry M. Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. J Child Adolesc Psychopharmacol. 2008;18(2):140\u2013156.","DOI":"10.1089\/cap.2006.0007"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Findling RL, Reed MF, O\u2019Riordan MA et al. Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(7):792\u2013800.","DOI":"10.1097\/01.chi.0000219832.23849.31"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Findling RL, Reed MF, O\u2019Riordan MA et al. A 26-week open-label study of quetiapine in children with conduct disorder. J Child Adolesc Psychopharmacol. 2007;17(1):1\u20139.","DOI":"10.1089\/cap.2006.0027"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Kronenberger WG, Giauque AL, Lafata DE et al. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct\/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17(3):334\u2013347.","DOI":"10.1089\/cap.2006.0012"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Masi G, Pisano S, Pfanner C et al. Quetiapine monotherapy in adolescents with bipolar disorder comorbid with conduct disorder. J Child Adolesc Psychopharmacol. 2013;23(8):568\u2013571.","DOI":"10.1089\/cap.2013.0063"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Naguy A. Low-dose quetiapine complements stimulant response in attention deficit hyperactivity disorder and more. Ther Adv Psychopharmacol. 2016;6(6):384\u2013385.","DOI":"10.1177\/2045125316672545"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Golubchik P, Sever J, Weizman A. Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol. 2011;34(6):216\u2013219.","DOI":"10.1097\/WNF.0b013e31823349ac"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Findling RL, McNamara NK, Gracious BL et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol. 2004;14(2):287\u2013294.","DOI":"10.1089\/1044546041649129"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Martin A, Koenig K, Scahill L et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 1999;9(2):99\u2013107.","DOI":"10.1089\/cap.1999.9.99"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette\u2019s disorder. J Child Adolesc Psychopharmacol. 2003;13(3):295\u2013299.","DOI":"10.1089\/104454603322572624"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Pathak S, Johns ES, Kowatch RA. Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. J Child Adolesc Psychopharmacol. 2005;15(4):696\u2013702.","DOI":"10.1089\/cap.2005.15.696"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Black DW, Zanarini MC, Romine A et al. Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2014;171(11):1174\u20131182.","DOI":"10.1176\/appi.ajp.2014.13101348"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Court A, Mulder C, Kerr M et al. Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: A pilot study. J Psychiatr Res. 2010;44(15):1027\u20131034.","DOI":"10.1016\/j.jpsychires.2010.03.011"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Cohen LS. Quetiapine in treatment-resistant obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2003;42(6):623\u2013624.","DOI":"10.1097\/01.CHI.0000046854.56865.DE"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Naguy A, Alamiri B. Treatment-resistant OCD - A psychopharmacological \u2018touche d\u2019art\u2019. Asian J Psychiatr. 2018;34:98\u201399.","DOI":"10.1016\/j.ajp.2018.04.025"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Stamouli S, Lykouras L. Quetiapine-induced obsessive-compulsive symptoms: a series of five cases. J Clin Psychopharmacol. 2006;26(4):396\u2013400.","DOI":"10.1097\/01.jcp.0000227809.60664.6d"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Stathis S, Martin G, McKenna JG. A preliminary case series on the use of quetiapine for posttraumatic stress disorder in juveniles within a youth detention center. J Clin Psychopharmacol. 2005;25(6):539\u2013544.","DOI":"10.1097\/01.jcp.0000186901.79861.e2"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Junior JABC, Guzman CS, Tavares H. Quetiapine for the treatment of trichotillomania. Braz J Psychiatry. 2008;30(4):402.","DOI":"10.1590\/S1516-44462008000400019"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Joyce C, Witcher R, Herrup E et al. Evaluation of the Safety of Quetiapine in Treating Delirium in Critically Ill Children: A Retrospective Review. J Child Adolesc Psychopharmacol. 2015;25(9):666\u2013670.","DOI":"10.1089\/cap.2015.0093"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Boafo A, Greenham S, Sullivan M et al. Medications for sleep disturbance in children and adolescents with depression: a survey of Canadian child and adolescent psychiatrists. Child adolesc Psychiatry Ment Health. 2020;14:10.","DOI":"10.1186\/s13034-020-00316-8"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:33:33Z","timestamp":1791315213000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/quetiapine-and-paediatric-psychiatrica-evidence-or-diffidence\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4532","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}